| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA723: Bimekizumab for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | bimekizumab (Bimzelx®) |
| Formulation | 160 mg solution for injection |
| Reference number | 4038 |
| Indication | Treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy |
| Company | UCB Pharma Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/07/2021 |
| NICE guidance | TA723: Bimekizumab for treating moderate to severe plaque psoriasis |